Notal Vision (נוטל וויז'ן)

Tel Aviv-Yafo, Israel

Notal Vision has developed a cloud-based platform designed to effectively and efficiently address large unmet diagnostic, economic, and social needs in the area of ophthalmology. The company's integrated platform uses AI algorithms to detect and provide diagnostic decision support, driving at-home testing and patient-activated treatment. Using a monthly recurring subscription service model, the platform provides the basis for cost-effective solutions that can enhance both compliance and outcomes. Notal's ForeseeHome is an FDA-approved home monitoring test that supports earlier detection of wet age-related macular degeneration (AMD) in people with intermediate dry AMD. It is available only by physician order and covered by US Medicare. Notal also develops optical coherence tomography (OCT) solutions, noninvasive imaging technology for viewing retinal anatomy and assessing the need for treatment of age-related eye diseases that lead to blindness. In December 2018, Notal's Home OCT was granted Breakthrough status by the FDA and selected to participate in the FDA's OCT Innovation Pilot program. Notal's OCT Analyzer is a computational image analysis algorithm designed to provide automated detection of fluid in exudative retinal diseases.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Notal Vision (נוטל וויז'ן) on @MedStartr Today #Ophthalmology #EyeDisorders #Vision #AIML #Diagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/wABOsfpKvKQ

Get Involved in Notal Vision (נוטל וויז'ן)

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2000
Website: www.notalvision.com/

Disease Areas

Ophthalmology Eye Disorders Vision

Technologies

Cloud-Based PlatformAI AlgorithmsDiagnostic Decision SupportAt-Home Testing

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Notal Vision (נוטל וויז'ן)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.